聚磷酸盐
核苷二磷酸激酶
寡核苷酸
核苷
生物化学
化学
酶
核苷酸
激酶
核糖核酸
醋酸激酶
组合化学
计算生物学
磷酸盐
三磷酸核苷
三磷酸腺苷
合成生物学
核苷酸转移酶
生物催化
分离(微生物学)
钥匙(锁)
碱基
作者
Qinglong Meng,Caecilie M. M. Benckendorff,Charlotte Morrill,Ying Zhuo,Annette Egerström,Aisling Ní Cheallaigh,Sasha R. Derrington,Richard Obexer,Mary Ortmayer,Colin Levy,James Finnigan,Simon J. Charnock,Nicholas J. Turner,Gavin J. Miller,Sarah L. Lovelock
标识
DOI:10.1038/s41467-025-67366-4
摘要
The rapid emergence of RNA therapeutics has highlighted the need for more efficient, scalable and sustainable methods for their manufacture. Biocatalytic approaches hold particular promise, but rely on a secure, sustainable and low-cost supply of nucleoside triphosphate (NTP) building blocks, including those containing chemical modifications. Here we report the development of a biocatalytic approach and engineered enzymes to convert widely available nucleosides into NTPs featuring pharmaceutically relevant modifications using inexpensive phosphate donors. Importantly our strategy obviates the need for ATP as a phosphate donor that complicates NTP isolation using existing methods. To showcase the utility of our approach, we employ an engineered acid phosphatase, polyphosphate kinase and acetate kinase to produce 2'-O-methoxyethyl-ATP (2'-MOE-ATP) and 2'-fluoro-ATP, key building blocks of commercial therapeutics. Finally, we show that crude NTPs from our process can be used directly in enzymatic oligonucleotide synthesis, obviating the need for costly NTP isolation or purification steps.
科研通智能强力驱动
Strongly Powered by AbleSci AI